EXO-OC Study Hampered by Biobank Sample Variability

Sample Quality Problems Stall EXO-OC Clinical Validation

INOVIQ Ltd (ASX:IIQ) has disclosed that its recent retrospective OC2200 clinical study for the EXO-OC ovarian cancer diagnostic test encountered significant sample quality issues. These problems arose from provider-specific pre-analytical variations affecting the integrity of key biomarkers, including miRNA and CA125 protein levels. The inconsistencies across biorepositories rendered the samples unsuitable for meaningful test performance evaluation.

The company explained that these variations likely stem from differences in sample collection, handling, and storage prior to receipt, factors that are notoriously difficult to control in retrospective studies. Such pre-analytical factors impact extracellular vesicle and miRNA biomarker stability, which are critical to the EXO-OC test’s accuracy. INOVIQ is now conducting a comprehensive technical review to inform future validation studies and refine both biomarkers and the machine learning algorithm underpinning the test.

Governance and Management Response

The study was conducted under established governance frameworks, including Human Research Ethics Committee approvals and structured project management. Upon identifying the sample quality issues, management promptly escalated the findings to the Board, which is overseeing corrective actions. The Board affirmed that development risks were identified and managed according to standard diagnostic development practices, balancing risk mitigation with cost and timelines.

Management accountability was underscored by the decision not to pay bonuses for FY25 due to poor share price performance, with similar outcomes anticipated for FY26 pending review. The Board also outlined plans to strengthen study design, quality controls, and governance to restore shareholder confidence and accelerate value-creating milestones.

Commercialisation Strategy and Financial Position

Despite the setback, INOVIQ remains committed to commercialising EXO-OC initially as a Laboratory Developed Test (LDT) in the US, targeting early detection of ovarian cancer in high-risk women. Parallel development of an In Vitro Diagnostic (IVD) for broader screening in asymptomatic, average-risk populations is planned, leveraging regulatory pathways including Breakthrough Device Designation submissions and prospective pivotal clinical trials.

INOVIQ reported cash reserves of $9.35 million as of 30 June 2026, providing funding into 2027 with disciplined capital allocation focused on advancing both the EXO-OC diagnostic and CAR-exosome therapeutic programs. The company is actively engaging potential partners and Contract Research Organisations to support technology transfer, assay optimisation, and final validation in CLIA-certified laboratories.

Clinical and Market Opportunity Remain Intact

The EXO-OC test combines exosomal miRNA biomarkers with CA125 protein levels, analysed through a proprietary machine learning algorithm, to enable early and accurate ovarian cancer detection. Previous studies demonstrated promising sensitivity and specificity metrics, although the recent sample quality issues highlight the challenges of retrospective biobank studies.

INOVIQ’s dual-path commercialisation approach aims to balance speed to market via LDT offerings with broader adoption and reimbursement potential through IVD approval. The addressable market includes over 240 million women globally in screening populations, with substantial opportunities in both high-risk and average-risk cohorts.

While the precise impact on development timelines remains uncertain, the company’s strategic review and partner discussions will be key to navigating the next phase of clinical validation and commercialisation.